0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150
Percent
of
bases
Depth of coverage
Roche MedExome Supplier A's Clinical Research Exome
Fold 80 Base Penalty
Fold additional sequencing needed to
bring 80% of the targeted bases up to
the original mean coverage depth
MedExome 1.95
Competitor A 2.21
0.0
10.0
20.0
30.0
40.0
50.0
60.0
<90% 90-97% 97-100% 100%
Percent
of
total
GeneTests
genes
covered
Percent of each GeneTests gene's coding bases covered at ≥20X
Roche MedExome
Supplier A's Clinical Research Exome
Figure 1. Roche's SeqCap EZ MedExome kit demonstrated sustained
coverage at 100% and more uniform coverage than Supplier A's
Clinical Research Exome. Fold 80 base penalty calculation shows more
uniform capture for the SeqCap EZ MedExome Kit. This graph is of one
representative sample from one 6-plex capture per product. For Supplier A's
product, the targets are unpadded. SeqCap EZ MedExome kit target refl ects
empirical target across all metrics. All reads were subsampled to 60 million
for assessment.*
Figure 2. With SeqCap EZ MedExome, 53% of medically relevant genes
are covered at 100% (≥20X coverage) vs. 6% by Supplier A's Clinical
Research Exome. Percentage of bases covered at ≥20X for each consolidated
target was determined using GATK (DepthOfCoverage), summarized by gene.
Supplier A kit's data was generated by a third-party sequencing service provider,
following Supplier A's protocol. All reads were subsampled to 60 million for
assessment, then subjected to the same bioinformatics pipeline for analysis.*
Reveal more about the exome
Learn more about how the SeqCap EZ
MedExome Target Enrichment Kit can
improve your whole exome sequencing.
Visit sequencing.roche.com/medexome.html
or call 800-262-4911 .
Roche Diagnostics Corporation
9115 Hague Road
Indianapolis, Indiana 46256
For life science research only.
Not for use in diagnostic procedures.
For patent license limitations for individual products please refer to:
www.technical-support.roche.com
* Roche data on fi le.
NIMBLEGEN and SEQCAP are trademarks of Roche.
All other product names and trademarks are the property of their respective owners.
© 2016 Roche PP-US-05710-0816
Supplier A's Clinical Research Exome Roche SeqCap EZ MedExome
Figure 3. SeqCap EZ MedExome shows reduced GC bias in sequencing
coverage with uniform coverage over a broad range of GC content.
One-hundred nanograms of extracted NA12898 DNA was subjected to perfor-
mance evaluation by both kits. Performance was determined post-enrichment
following SeqCap EZ User's Guide v5.1. Supplier A's kit data was generated by
a 3rd party service provider following vendor's protocol. All reads were sub-
sampled to 60 million for assessment. Sequencing reads were subjected to the
same bioinformatics pipeline for analysis. GC composition of all consolidated
target regions (empirical target for MedExome, unpadded target for Supplier
A) was determined and plotted against mean depth of coverage calculated by
GATK DepthOfCoverage for all consolidated target regions.*